Lupin acquires Huminsulin in India to strengthen diabetes care portfolio

Global pharma company Lupin announced the acquisition of Huminsulin in India from Eli Lilly and Company (Lilly), aiming to expand its diabetes care portfolio. Lupin has been marketing the Huminsulin range under existing distribution and promotion agreements with Lilly in India.

The Huminsulin product line includes Insulin Human formulations such as Huminsulin R, Huminsulin NPH, Huminsulin 50/50, and Huminsulin 30/70. These products are prescribed for the treatment of type 1 and type 2 diabetes mellitus to improve blood sugar control in adults and children. Insulin therapy is a critical component of managing type 1 diabetes and becomes increasingly necessary for type 2 diabetes as the condition progresses.

The prevalence of diabetes in India highlights the importance of accessible insulin therapies. Insulin Human remains a key treatment prescribed for the management of both type 1 and type 2 diabetes, often in combination with other therapies.

“This acquisition is strategic to our ongoing efforts to expand our diabetes portfolio and provide high-quality, affordable health care to our patients. It reinforces our unwavering commitment to combating diabetes and providing comprehensive care,” said Nilesh Gupta, Managing Director, Lupin.

Rajeev Sibal, President – India Region Formulations at Lupin, commented on the significance of the acquisition, stating, “Lupin has been at the forefront of providing holistic diabetes care to patients. This acquisition further strengthens our diabetes portfolio and enables us to offer a broad range of human insulin options to millions of patients, thereby helping them lead healthier lives.”

With the acquisition of Huminsulin, Lupin aims to enhance its capabilities in addressing the needs of diabetes patients, reaffirming its position as a key player in comprehensive diabetes care solutions.